Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewJP 1302 dihydrochloride
说明： Potent and selective α2C antagonist
化学名： N-[4-(4-Methyl-1-piperazinyl)phenyl]-9-acridinamine dihydrochloride
纯度： ≥99% (HPLC)
生物活性 for JP 1302 dihydrochloride
JP 1302 dihydrochloride is an α2C-adrenoceptor antagonist that displays ~ 50-fold selectivity over other α2-adrenoceptor subtypes (Ki values are 28, 1470, 1700 and 3150 nM for human α2C, α2B, α2D and α2A subtypes respectively). Potently antagonizes adrenalin-stimulated 35GTPγS binding in vitro (KB = 16 nM) and produces antidepressant and antipsychotic-like effects in vivo.
技术数据 for JP 1302 dihydrochloride
| 分子量 | 441.4 |
| 公式 | C24H24N4.2HCl |
| 储存 | Store at -20°C |
| 纯度 | ≥99% (HPLC) |
| CAS Number | 1259314-65-2 |
| PubChem ID | 49855035 |
| InChI Key | VVZOADYFJAJZGL-UHFFFAOYSA-N |
| Smiles | CN(CC5)CCN5C(C=C4)=CC=C4NC2=C3C(C=CC=C3)=NC1=CC=CC=C12.Cl.Cl |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for JP 1302 dihydrochloride
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| water | 44.14 | 100 |
制备储备液 for JP 1302 dihydrochloride
以下数据基于产品分子量 441.4。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.27 mL | 11.33 mL | 22.66 mL |
| 5 mM | 0.45 mL | 2.27 mL | 4.53 mL |
| 10 mM | 0.23 mL | 1.13 mL | 2.27 mL |
| 50 mM | 0.05 mL | 0.23 mL | 0.45 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for JP 1302 dihydrochloride
参考文献 for JP 1302 dihydrochloride
参考文献是支持产品生物活性的出版物。
Tricklebank (2007) JP-1302: a new tool to shed light on the roles of α2C-adrenoceptors in brain. Br.J.Pharmacol. 150 381 PMID: 17220912
Sallinen et al (2007) Pharmacological characterization and CNS effects of a novel highly selective α2C-adrenoceptor antagonist JP-1302. Br.J.Pharmacol. 150 391 PMID: 17220913
If you know of a relevant reference for JP 1302 dihydrochloride, please let us know.
按产品操作查看相关产品
关键词: JP 1302 dihydrochloride, JP 1302 dihydrochloride supplier, Potent, selective, α2C-adrenoceptor, alpha2C-adrenoceptors, α2c-adrenergic, alpha2c-adrenergic, a2c-adrenoceptor, antagonists, Receptors, JP1302, dihydrochloride, Adrenergic, Alpha-2, 2666, Tocris Bioscience
1 篇 JP 1302 dihydrochloride 的引用文献
引用文献是使用了 Tocris 产品的出版物。 JP 1302 dihydrochloride 的部分引用包括：
Jiang et al (2015) SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway. Mol Med Rep 18 PMID: 25522427
您是否知道使用了 Tocris JP 1302 dihydrochloride 的优秀论文？ 请告知我们.
JP 1302 dihydrochloride 的评论
目前没有该产品的评论。 Be the first to review JP 1302 dihydrochloride and earn rewards!
Have you used JP 1302 dihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.